• HOME
  • ABOUT
    • About Us
    • Our History
  • THYROID INFO
    • About Thyroid Disease
    • Testing & Diagnosis
    • Treatment Options
    • Find a Doctor
    • Recommend a Doctor
  • RESOURCES
    • Supporting Evidence
    • Find a Doctor
    • Patient Forums
    • Useful Websites
  • PRODUCTS
    • Supplements
    • Helpful Books
    • Thyroid Programs
    • Other Health Products
  • FAQ
    • FAQ for Patients
    • FAQ for Physicians
  • TAKE ACTION
    • Join Our Network
    • Ways to Help
    • Make a Donation
  • BLOG
    • Blog
    • Submit to Our Blog
  • CONTACT
    • Contact Us
    • Partners and Affiliates
ThyroidChange

New Study Reports Patient Satisfaction of Armour Thyroid Over Levothyroxine-only Therapy

10/29/2014

0 Comments

 
Picture
A recently published study in the Journal of Endocrinology, Diabetes & Obesity reports patient satisfaction of individuals on both Armour Thyroid (desiccated thyroid medication) and levothyroxine (T4-only) medication. The patients were given a course of treatment of both medications and then were asked to rate their preference. The results of the study indicate that the majority of the test subjects preferred desiccated thyroid to levothyroxine. The research was conducted to ensure that a placebo effect was not the cause for preference. The study was conducted without funding from any public, commercial, or not-for-profit agencies and was presented in part at the 83rd Annual Meeting of the American Thyroid Association in 2013.

The research was conducted by endocrinologists Gary M. Pepper, MD and Paul Y. Casanova-Romero, MD. Dr. Pepper recently became acquainted with ThyroidChange and reported his enthusiasm to become a supporter of our cause. He has served as Associate Professor of Medicine at New York University School of Medicine and Director of the Diabetes Treatment Center at Brooklyn Hospital. He has also served as Chief of the Division of Endocrinology for New York Medical College, Bronx, New York. Dr. Pepper's independent research in thyroid, adrenal and pituitary diseases can be found in top medical journals including the Journal of Clinical Endocrinology and Metabolism.


The following is a summary of the study, Conversion to Armour Thyroid from Levothyroxine Improved Patient Satisfaction in the Treatment of Hypothyroidism

Abstract:  The use of Armour Thyroid (desiccated thyroid) in the treatment of hypothyroidism has generated debate among endocrinologists although there is evidence that a significant percentage of patients prefer this medication to T4-only replacement strategies. In this retrospective analysis we investigate the preference for replacement therapy of patients with persistent subjective symptoms of hypothyroidism on T4-only treatment who subsequently switched to Armour Thyroid (AT).

Methods:  450 consecutive patients being treated for hypothyroidism were screened. Of these, 154 had been switched from either generic or brand T4 replacement to AT for treatment of persistent symptoms of hypothyroidism. Patients undergoing treatment for thyroid cancer or on suppression therapy for nodular thyroid disease were excluded. Patients were instructed to have their blood sampled for thyroid function testing in the morning after taking their medication. After a minimum of 4 weeks on medication patients were asked to compare AT treatment versus T4-only treatment using a 5 point satisfaction rating scale. Results are reported as mean ± SD.

Results: On a 5 point Satisfaction Rating Scale with “5” indicative of the highest level of satisfaction, 117 (78.0%) patients gave a score of greater than “3” in preference for AT. Three patients treated with AT and one treated with LT4 reported adverse events, all minor. TSH was 1.30 ± 1.9 mIU/L and T3 1.81 ± 0.78 pmol/L on L-T4 monotherapy while TSH was 1.27 ± 2.2 mIU/L and T3 2.31 ± 1.33 pmol/L on AT (NS for TSH and p<0.003 for T3 ). T4 to T3 ratio on L-T4 monotherapy was 8.45 ± 3.7 while it was 4.70 ± 2.0 (p<0.001) on AT. There was no significant change in weight after switching to AT.

Conclusion: AT treatment was preferred over LT4 replacement therapy by 78% of patients with hypothyroidism in the sub-group with persistent subjective complaints while on T4-only therapy. No serious adverse events were noted while on AT treatment including 30 subjects aged 65 yrs or older. AT could be a reasonable alternative choice for treating this sub-group of patients with hypothyroidism.

0 Comments



Leave a Reply.

    Picture
    Subscribe! 
    Receive our newsletter and the latest blog articles.

    Categories

    All
    Adrenal Fatigue
    Diet & Food
    Hashimoto's Thyroiditis
    Patient Stories
    Q&A Doctor Series
    Recent News
    Symptoms
    Testing & Diagnosis
    Thyroid Cancer
    Treatment Options

    Archives

    January 2018
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    January 2014
    October 2013
    September 2013
    August 2013
    July 2013
    May 2013
    April 2013
    March 2013
    February 2013
    July 2012

    Donate
    Help ThyroidChange by making a gift today. 
    ​Submit
    Click here to learn how you can submit a patient story or thyroid health article to our blog!
    The opinions in our blog do not necessarily express the official feelings or opinions of ThyroidChange.

    RSS Feed

CONTACT
© 2018 ThyroidChange, LLC.  All rights reserved.

ABOUT
Our Mission
Our History
Get Involved
​
Legal Notice
​

QUICK LINKS
Find a Doctor
Thyroid Info
Resources

Blog
TRANSLATIONS
50+ Languages
Picture
✕